(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
UN experts urge investigation into Israel’s killing of Lebanese journalists - 2Israel reports second missile fire from Yemen since start of Iran war
- 3CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- 4Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- 5Google to Use Natural Gas to Power Massive Data Center in Texas
- Vote in favor of your #1 Kind of Cap
- Figurine of a woman and a goose offers peek at prehistoric beliefs
- Bayer sues COVID vaccine makers over mRNA technology
- UB professor shares his experience on almost becoming an astronaut
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Virtual reality opens doors for older people to build closer connections in real life
- Ocean side Locations for a Family Excursion
- 6 Exceptionally Appraised Summer Travel Objections
- Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
